Repligen Corporation filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the Securities and Exchange Commission on October 30, 2026, disclosing a net loss driven in part by an intangible asset impairment charge recorded in the quarter.

Key Highlights

  • Quarterly net loss: Repligen reported a net loss of $38,432 thousand for the three months ended September 30, 2026, compared to net income of $14,911 thousand in the same period of 2025.
  • Intangible asset impairment: The company recorded intangible asset impairment charges of $41,242 thousand in the third quarter of 2026, with no comparable charge in Q3 2025.
  • Total revenue: Total revenue for Q3 2026 was $209,314 thousand, up from $188,805 thousand in Q3 2025, with product revenue of $209,270 thousand.
  • Nine-month revenue: Total revenue for the nine months ended September 30, 2026 was $607,697 thousand, compared to $540,343 thousand for the same period in 2025.
  • Loss on sale of business: The filing reported a loss on sale of business of $13,694 thousand for the nine months ended September 30, 2026.
  • Total assets: Total assets stood at $2,926,408 thousand as of September 30, 2026, compared to $2,949,699 thousand at December 31, 2025.
  • Basic loss per share: Basic loss per share for Q3 2026 was $(0.68), versus basic earnings per share of $0.27 in Q3 2025.

Repligen Reports Q3 2026 Loss Amid Impairment and Business Sale Charges

According to the filing, Repligen Corporation (NASDAQ:RGEN), a bioprocessing technology company headquartered in Waltham, Massachusetts, reported a net loss of $38,432 thousand for the three months ended September 30, 2026. The company attributed a significant portion of the quarter's operating pressure to intangible asset impairment charges of $41,242 thousand, which appeared in the period with no comparable charge recorded in the prior-year quarter. Total costs and operating expenses for Q3 2026 were $238,860 thousand, compared to $171,980 thousand in Q3 2025.

The filing disclosed that product revenue grew to $209,270 thousand in Q3 2026 from $188,766 thousand in Q3 2025, and nine-month product revenue rose to $607,566 thousand from $540,232 thousand a year earlier. Operating loss for the three months ended September 30, 2026 was $(29,546) thousand, contrasting with operating income of $16,825 thousand in the comparable 2025 period. For the nine months ended September 30, 2026, the company reported operating income of $370 thousand, down from $37,299 thousand in the nine months ended September 30, 2025.

The company also disclosed restructuring activities and other charges of $6,180 thousand for the nine months ended September 30, 2026, and a loss on sale of business of $13,694 thousand for the same period. On the balance sheet, cash and cash equivalents increased to $726,960 thousand at September 30, 2026, from $566,021 thousand at December 31, 2025. Convertible Senior Notes due 2028, net, were reported at $555,596 thousand. Common shares issued and outstanding were 56,692,755 at September 30, 2026, compared to 56,325,429 at December 31, 2025, according to the filing.

What Was Disclosed

Repligen filed its Form 10-Q for the quarterly period ended September 30, 2026, reporting a net loss of $38,432 thousand for Q3 2026, driven by a $41,242 thousand intangible asset impairment charge, a loss on sale of business, and higher operating expenses compared to the prior-year period.